NFKB1 and plasma cell myeloma: Still, proteasome inhibitors (which block IκB degradation for canonical and noncanonical signaling) have been quite effective for the treatment of multiple myeloma [15], and they appear to act, at least in part, due to their inhibitory effects on NF-κB signaling.